GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kancera AB (OSTO:KAN) » Definitions » EBITDA Margin %

Kancera AB (OSTO:KAN) EBITDA Margin % : -70,778.57% (As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Kancera AB EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Kancera AB's EBITDA for the three months ended in Dec. 2024 was kr-9.91 Mil. Kancera AB's Revenue for the three months ended in Dec. 2024 was kr0.01 Mil. Therefore, Kancera AB's EBITDA margin for the quarter that ended in Dec. 2024 was -70,778.57%.


Kancera AB EBITDA Margin % Historical Data

The historical data trend for Kancera AB's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kancera AB EBITDA Margin % Chart

Kancera AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -700.19 -2,661.33 -6,906.51 -5,994.40 -329,721.43

Kancera AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,285.78 - - - -70,778.57

Competitive Comparison of Kancera AB's EBITDA Margin %

For the Biotechnology subindustry, Kancera AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kancera AB's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kancera AB's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Kancera AB's EBITDA Margin % falls into.


;
;

Kancera AB EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Kancera AB's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-46.161/0.014
=-329,721.43 %

Kancera AB's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-9.909/0.014
=-70,778.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kancera AB  (OSTO:KAN) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Kancera AB EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Kancera AB's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kancera AB Business Description

Traded in Other Exchanges
N/A
Address
Karolinska Institutet Science Park, Banvaktsvagen 22, Solna, SWE, 171 48
Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and KAND145 are developed to effectively counteract hyperinflamation in various disease states and thereby protect vital organs in conjunction with myocardial infarction and severe viral infections. Kancera is planning two phase II clinical trials, in covid-19 and in cardiac patients. The company conducts research and development within the Karolinska Institute Science Park in Stockholm.

Kancera AB Headlines

No Headlines